Adastra announces successful Public Hearing at the Langley Civic Facility for its site re-zoning

May 13th, 2019 – Adastra Labs Holdings Ltd. (“Adastra” or the “Company”) announces successful Public Hearing at the Langley Civic Facility for its site re-zoning.  Adastra subsidiary Chemia Analytics Head of Laboratory Priyanka Nalawade noted, “The Public Hearing went very smoothly with good discussion about the measures Adastra is taking to abate and control odours at the facility.  We have been designing our facility to meet and exceed future Metro Vancouver emissions control regulations, still in draft form, for air quality at cannabis processing facilities.”  The Adastra team has designed the facility to use HEPA intake filtration and activated charcoal exhaust filtration for air quality control to assist it to meet Good Manufacturing Practice (GMP) standards.  CEO Andy Hale explained the lengths Adastra has gone to ensure air quality standards will be exceeded and odours completely abated, particularly given the nature of the facility as a standard processor and analytical testing lab versus a standard cultivator.

 With 1st Reading, 2nd Reading and the Public Hearing successfully complete, the re-zoning text amendment for Adastra’s Gloucester Industrial Park facility will continue with a 3rd and Final Reading together on the 27th of May in the Langley Civic Facility where the Township of Langley Councilmembers will cast their final votes.  The re-zoning effort marks the first time in the Lower Mainland of British Columbia a site will be specifically zoned for cannabis standard processing and analytical testing.

Further Information

For further information, please contact:

Andy Hale, CEO

Email: info@adastralabs.ca

About Adastra Labs Holdings Ltd.

In Canada, Adastra (through its wholly owned subsidiaries, Adastra Labs Inc. and Chemia Analytics Inc.) is in the application process to become a Standard Processor and Analytical Testing Laboratory under the Cannabis Act administered by Health Canada, with licences to produce cannabis extracts and provide third party analytical testing services. These licences will further enable Adastra and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licensed entities and internationally in jurisdictions where medical cannabis extraction products are legal.

The Company’s operations include a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing and laboratory testing by late 2019, from which it expects to produce significant amounts of cannabis oil and/or hemp oil for the Canadian wholesale medical and recreational markets.

The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, Adastra will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to:  Adastra’s expectations concerning an increase in its production capacity. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Adastra Labs Holdings Ltd.

Scroll to Top